Influence of Chronic Opioid Delta Receptor Antagonism on Blood Pressure Development and Tissue Contents of Catecholamines and Endogenous Opioids in Spontaneously Hypertensive Rats

References

• Quock R. M., Vaughn L. K., Kouchich F. J. Influence of chronic naloxone treatment on development of hypertension in the spontaneously hypertensive rat. Naunyn-Schmiedeberg's Arch Pharmacol 1984; 3256: 88–90
   Google Scholar
• Head R. J. Hypernoradrenergic innervation: Its relationship to functional and hyperplastic changes in the vascula-ture of the spontaneously hypertensive rat. Blood Vessels 1989; 26: 1–20
   PubMedGoogle Scholar
• Mosqueda-Garcia R., Kunos G. Opiate receptors and the endorphin-mediated cardiovascular effects of clonidine in rats: Evidence for hypertension-induced μ-type to delta-type changes. Proc Natl Acad Sci USA 1987; 84: 8637–8641
   PubMed Web of Science ®Google Scholar
• Versteeg D. H.G., Palkovitz M., Guyton I. V. Catecholamine content of individual brain regions of spontaneously hypertensive rats (SH rats). Brain Res 1976; 112: 429–438
   PubMed Web of Science ®Google Scholar
• Olson G. A., Olson R. D., Kastin A. J. Endogenous opiates: 1988. Peptides. 1989; 10: 1253–1280
   Google Scholar
• Gormley J. J., Morley J. S., Priestley T., Shaw J. S., Turnbell M. J., Wheeler H. In vivo evaluation of the opiate receptor antagonist ICI 154 129. Life Sci 1982; 31: 1263–1266
   PubMed Web of Science ®Google Scholar
• Leander J. D., Gesellchen P. D., Mendelsohn L. G. Opioid antinociceptive effects of delta-receptor antagonists. Pharmacol Biochem Behav 1988; 29: 351–355
   PubMed Web of Science ®Google Scholar
• Da Prada M., Zurcher G. Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomol range. Life Sci 1976; 19: 1161–1174
   PubMed Web of Science ®Google Scholar
• Lang R. E., Brückner U. B., Kempf B., Rascher W., Sturm V., Unger T., Speck G., Ganten D. Opioid peptides and blood pressure regulation. Clin Exp Hypertens 1982; 1–2(A4)249–269
   Google Scholar
• McDowell J., Kitchen I. Development of opioid systems: peptides, receptors and pharmacology. Brain Res Reviews 1987; 12: 397–421
   Web of Science ®Google Scholar
• Jackson C. H., Sewell R. D. E. Characterization of the effects of (±)-meptazinol, its individual enantiomers and N-methyl meptazinol on food consumption in the rat. Br. J. Pharmac. 1986; 88: 689–695
   PubMed Web of Science ®Google Scholar
• Szabo B., Hedler L., Ensinger H., Starke K. Opioid peptides decrease noradrenaline release and blood pressure in the rabbit at peripheral receptors. Naunyn-Schmiedeberg's Arch Pharm 1986; 332: 550–556
   Google Scholar
• Illes P., Bucher B. Opioid peptides and blood pressure regulation, K. O. Stumpe, K. Kraft, A. I. Faden. Springer Verlag, Berlin, Heidelberg, New York 1988; 190–206
   Google Scholar
• Nakamura M., Kamata K., Inoue H., Inaba M. Effect of intracerebroventricular administration of opioid peptides on basal serum adrenaline levels in conscious rats. Japan J Pharma-col 1988; 47: 151–157
   PubMedGoogle Scholar
• Hökfelt T., Elde R., Johansson O., Terenius L., Stein L. The distribution of enkephalin-immunoreactive cell bodies in the rat central nervous system. Neurosci Lett 1977; 5: 25–31
   PubMed Web of Science ®Google Scholar
• Tanaka M., Yoshishige I., Akira T., Tsujimaru S., Shirao I., Oguchi M. Met-enkephalin, injected during the early phase of stress, attenuates stress-induced increase in noradrenaline release in rat brain regions. Pharmacol Biochem Behav 1989; 32: 791–795
   PubMed Web of Science ®Google Scholar
• Baron S. A., Testa F. M., Gintzler A. R. Simultaneous quantitation of norepinephrine, dopamine and serotonin in brain during and following chronic naltrexone administration. Brain Res 1985; 340: 192–198
   PubMed Web of Science ®Google Scholar
• Sharma T. R., Chan W. C., Gintzler A. R. Effect of chronic naltrexone administration and its withdrawal on the regional activity of neurons that contain norepinephrine, dopamine and serotonin. Brain Res 1988; 442: 379–386
   PubMed Web of Science ®Google Scholar
• Zukin R. S., Sugarman J. R., Fitz-Syage M. L., Gardner E. L., Zukin S. R., Gintzler A. R. Naltrexone-induced opiate receptor supersensitivity. Brain Res 1982; 245: 285–292
   PubMed Web of Science ®Google Scholar
• Simonyi A., Kanyiksa B., Szentendrei T., Fekete M. I. K. Effect of chronic morphine treatment on the adrenaline biosynthesis in adrenals and brain regions of the rat. Biochem Pharm 1988; 37: 749–752
   PubMed Web of Science ®Google Scholar
• Tsai C. F., Lin M. T. Pain sensitivity, thermal capability, and brain monoamine turnover in hypertensive rats. Am J Physiol 1987; 253: R 910–916
   Google Scholar
• Brody M. J., O'Neill T. P., Porter J. P. Role of central catecholaminergic systems in pathogenesis and treatment of hypertension. J Cardiovasc Pharmacol 1984; 6: 727–741
   PubMedGoogle Scholar
• Howes L. G., Summers R. G. Changes in brainstem and spinal adre-noceptor binding with ageing in spontaneously hypertensive and Wistar-Kyoto rats. Neurosci Lett 1985; 57: 247–250
   PubMed Web of Science ®Google Scholar
• Mastrianni J. A., Ingenito A. J. On the relationship between clonidine hypotension and brain β-endorphin in the spontaneously hypertensive rat: studies with alpha adrenergic and opiate blockers. J Pharmacol Exp Therap 1987; 242: 378–387
   PubMed Web of Science ®Google Scholar